Senior leadership team
Dr Adam M Hill
Chief Executive Officer
Adam is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last 2 decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Currently, Adam is a Visiting Professor in Global Health Innovation at Imperial College London and a Non-Executive Director of Imperial College Health Partners and MyRecovery.ai.
Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers.
We enable earlier detection and more effective treatment of cancer worldwide. Those whose lives have been impacted by our work continue to remind me of the tremendous importance of the work the Oncimmune team does every day.
Dr Adam M Hill
Chief Financial Officer
Matthew is a seasoned finance professional with over 25 years of corporate finance experience in a number of leading organisations and fast-growing companies. Matthew is a Chartered Accountant who initially spent 20 years as an investment banker with a focus on M&A as well as equity and debt funding for fast growing companies.
Over the past 10 years, Matthew has undertaken Chief Financial Officer roles for a number of life science companies, including, most recently CFO for Tusk Therapeutics, who was successfully divested for c.€650 million to Roche. Previously, Matthew was CFO at Sphere Medical Holding plc where he was appointed to lead the company’s successful IPO and prior to that was CFO of IS Pharma plc, where he was closely involved in the merger of IS Pharma plc and Sinclair Pharma plc.
We’re at one of the most exciting times in Oncimmune’s history as we partner with leading biopharmaceutical and diagnostic companies around the world to make our products and immune expertise available for earlier detection and improved treatments of cancer.
Chief Commercial Officer
Matt has over 18 years of commercial experience across a number of global pharmaceutical companies. He has held global and regional senior leadership roles in the areas of oncology, immunology, haematology and rare diseases. His responsibilities included Regional Marketing, Alliance Management, Geographical Expansion, Global Launch Excellence and Business Development. Most recently Matt was the Head of Haematology for Growth and Emerging Markets at Takeda, with responsibility for c.$1 billion of revenue generation across a large portfolio of therapeutics.
Matt started his professional career in diagnostic laboratories in Haematology and Immunology. He holds a Bachelor of Medical Science, Master of Management and a Master of Business Administration.
Cancer remains one of the biggest challenges to health outcomes worldwide. Our expertise and products help to reduce these as we work relentlessly to provide access to our technology to improve lives impacted by cancer.
General Counsel and Company Secretary
Ron is a qualified lawyer with over 18 years of experience in advising international companies, including those in the bio-technology and healthcare sector. Ron began his career in the corporate team of Allen & Overy, in its London, Hong Kong and Bangkok offices, before moving to Baker & McKenzie, the international law firm. Ron has also held senior in-house positions, including in Barclays Bank and Genus Plc, where he was interim General Counsel over a 12 month period.
Most recently Ron was Senior Counsel at Smith & Nephew plc, the London-listed global medical devices company, where he led the legal team supporting the European commercial operations. Ron was a member of Smith & Nephew’s UK management team and took part in its European leadership team.
Ron has extensive international experience, having spent several years working in Asia and regularly advising on international transactions.
Ron graduated from the University of Birmingham with an LLB in Law & Business Studies. He is admitted to practice law in England and Wales.
Whatever our roles are at Oncimmune, enabling cancer to be diagnosed earlier and for people to have extra time is what we work towards every day.
Professor Tariq Sethi
Chief Scientific Officer
Tariq is a researcher, clinician and entrepreneur with over 35 years of combined academic and industry experience in the field of immunology, inflammation and lung cancer.
Prior to joining Oncimmune, Tariq was Chief Physician Scientist, Vice President in the Clinical Discovery Unit at AstraZeneca and Emeritus Professor of Respiratory Medicine Kings College London, having previously held the position of Vice President in AstraZeneca’s Respiratory Immunology Autoimmunity Translational Medicine Unit. Prior to this he was Head of Respiratory Medicine at Guy’s and St. Thomas’ and King’s College Hospital NHS Foundation Trusts, Professor of Respiratory Medicine King’s College London and formally Professor of Lung Cancer and Respiratory Science at the University of Edinburgh.
Tariq was educated at Cambridge and London Universities followed by hospital jobs in London. Tariq completed a PhD at the Imperial Cancer Research Fund London, was an MRC Travelling Fellow at the Scripps Research Institute California and a Wellcome Trust Senior Research Leave Fellow in Edinburgh.
His research interests focus on the interaction between inflammation and lung cancer and he continues to sit on the editorial board of THORAX. Tariq was formally a member of the Population Systems Medicine Board Medical Research Council UK, Chair of Asthma (UK) and member of the British Lung Foundation Scientific Committees. Tariq is also a Co-Founder of Galecto Biotech.